-
🟥 Member Webinar : Hemophilia Alliance Hosts – A Webinar From Novo Nordisk – Preapproval Information Exchange: Denecimig for the treatment of hemophilia A
🟥 Member Webinar : Hemophilia Alliance Hosts – A Webinar From Novo Nordisk – Preapproval Information Exchange: Denecimig for the treatment of hemophilia A
Date: Wednesday, September 23rd, 2026 Time: 1:00pm - 2:00pm ET WEBINAR TOPIC: Preapproval Information Exchange: Denecimig for the treatment of hemophilia A OBJECTIVES: Denecimig is a novel FVIIIa mimetic agent currently under investigation for the treatment of hemophilia A (congenital FVIII deficiency) with or without FVIII inhibitors. Denecimig has not been approved for any indication Read the full article...